Premlata Kumari, Rohit Singh, Avneet Kaur, Deweshri Nandurkar, Kishor Danao, Vijayshri Rokde, Ruchi S. Shivhare, Ujwala Mahajan, Amit B. Patel, R. Rajalakshmi, S. Ramkumar, Yousef Najajreh, Maha Awwad Khoury, A. Thiruvalluvar
TLDR Methods for creating diverse ring-shaped molecules and their uses.
We don't know much about this study yet.
We're maintaining the world's largest resposity of hair loss
research. You can help out the community by
sending a PDF of this study here
.
Not sure how to get a study's PDF? You can email the authors
of the study.
The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.
Creating a carrier solution for topical hair loss treatments using ethanol, propylene glycol or glycerin, and instructions on creating topical finasteride. Different recipes are provided with varying ratios of alcohol to humectant.
The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.